REG - AstraZeneca PLC - AstraZeneca enters into collaboration with CSPC

AstraZenecaAnnouncement

13/06/2025 09:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250613:nRSM6582Ma&default-theme=true

RNS Number : 6582M  AstraZeneca PLC  13 June 2025

13 June 2025

AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused
on AI-enabled research

AstraZeneca has entered a strategic research collaboration with Shijiazhuang
City-based CSPC Pharmaceuticals Group Limited. Working together on high
priority targets, the collaboration aims to advance the discovery and
development of novel oral candidates, with the potential to treat diseases
across multiple indications.

 

Under the terms of the agreement, AstraZeneca and CSPC agree to discover and
develop pre-clinical candidates for multiple targets with the potential to
treat diseases across chronic indications, including a pre-clinical small
molecule oral therapy for immunological diseases.

 

Sharon Barr, Executive Vice President and Head of BioPharmaceuticals R&D
said: "This strategic research collaboration underscores our commitment to
innovation to tackle chronic diseases which impact over two billion people
globally. Forming strong collaborations allows us to leverage our
complementary scientific expertise to support the rapid discovery of
high-quality novel therapeutic molecules to deliver the next-generation
medicines."

 

The research will be carried out by CSPC, in Shijiazhuang City and will
utilise their AI-driven, dual-engine efficient drug discovery platform. This
platform uses AI technology to analyse the binding patterns of target proteins
with existing compound molecules, conduct targeted optimization, with the aim
of selecting highly effective small molecules with excellent developability.

 

The collaboration furthers AstraZeneca's presence in China following the
$2.5bn investment in Beijing
(https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-invests-2-and-half-bn-in-beijing-r-and-d-and-manufacturing.html)
announced earlier this year and strengthens the ongoing collaboration with
CSPC.

 

Financial considerations

Under the terms of the agreement, CSPC will receive an upfront payment of $110
million, and is also eligible to receive up to $1.62 billion in potential
development milestone payments and up to $3.6 billion in sales milestone
payments, plus potential single digit royalties based on annual net sales of
the products.

 

Under the agreement, AstraZeneca will have rights to exercise options for
exclusive licenses to develop and commercialise worldwide candidates
identified under this agreement.

Notes

 

AstraZeneca (https://www.astrazeneca.com/)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on social media @AstraZeneca
(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

Matthew Bowden

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPKBBBPBKDAAD